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Brain biomarkers and pre-injury cognition
are associated with long-term cognitive
outcome in children with traumatic brain
injury
Amy A. Wilkinson1,2*, Maureen Dennis1,2,3ˆ, Nevena Simic4, Margot J. Taylor1,2,5, Benjamin R. Morgan5,
Helena Frndova6, Karen Choong7, Craig Campbell8, Douglas Fraser8, Vicki Anderson9,10, Anne-Marie Guerguerian2,6,
Russell Schachar2,11, Jamie Hutchison2,6*, For the Canadian Critical Care Trials Group (CCCTG) and The Canadian
Critical Care Translational Biology Group (CCCTBG)

Abstract
Background: Children with traumatic brain injury (TBI) are frequently at risk of long-term impairments of attention
and executive functioning but these problems are difficult to predict. Although deficits have been reported to vary
with injury severity, age at injury and sex, prognostication of outcome remains imperfect at a patient-specific level.
The objective of this proof of principle study was to evaluate a variety of patient variables, along with six brain-specific
and inflammatory serum protein biomarkers, as predictors of long-term cognitive outcome following paediatric TBI.
Method: Outcome was assessed in 23 patients via parent-rated questionnaires related to attention deficit hyperactivity
disorder (ADHD) and executive functioning, using the Conners 3rd Edition Rating Scales (Conners-3) and Behaviour Rating
Inventory of Executive Function (BRIEF) at a mean time since injury of 3.1 years. Partial least squares (PLS) analyses were
performed to identify factors measured at the time of injury that were most closely associated with outcome on (1) the
Conners-3 and (2) the Behavioural Regulation Index (BRI) and (3) Metacognition Index (MI) of the BRIEF.
Results: Higher levels of neuron specific enolase (NSE) and lower levels of soluble neuron cell adhesion molecule
(sNCAM) were associated with higher scores on the inattention, hyperactivity/impulsivity and executive functioning scales
of the Conners-3, as well as working memory and initiate scales of the MI from the BRIEF. Higher levels of NSE only were
associated with higher scores on the inhibit scale of the BRI.
Conclusions: NSE and sNCAM show promise as reliable, early predictors of long-term attention-related and executive
functioning problems following paediatric TBI.
Keywords: Attention, Executive functions, Traumatic brain injury, Serum biomarkers

Background
Following traumatic brain injury (TBI), children and
adolescents experience changes in both cognitive and
behavioural functioning [1]. These deficits are frequently
associated with damage to the frontal and temporal regions
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of the brain [2]. The frontal lobes are known to have protracted development throughout childhood and adolescence [3], thus are particularly vulnerable to insult, such as
TBI, experienced during development. Two cognitive areas
that are dependent on intact functioning of frontal networks, and thus frequently reported as impaired following
TBI, are executive functioning and attention [4].
Executive functioning is an umbrella term used to describe
a variety of abilities allowing purposeful, goal-directed,
problem-solving behaviour, including behavioural regulation,
planning and organizational skills, and self-monitoring [5].
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Deficits in executive functioning have been seen within the
first year [6, 7] and up to five [8] and 10 years [4] following
childhood TBI. At 10 years post-injury, 26% of those
who sustained a moderate TBI and 42% of those who
sustained a severe TBI had clinically significant impairments on measures of executive functioning [4].
Deficits in executive functioning have been variously
related to injury severity [4, 6–8], age at injury [6]
and socioeconomic status (SES) [6].
Behavioural symptoms of attention difficulties are observed as inattention, hyperactivity and impulsivity, which
are the primary symptoms associated with attention deficit
hyperactivity disorder (ADHD) [9]. These symptoms are
over-represented in children with TBI, with 20% of children
meeting ADHD criteria prior to the injury [10] and an
additional 18–20% of children experiencing de novo attention difficulties by two years post-injury [11, 12]. A relation
between injury severity and the development of attention
problems has been reported in some studies [11–14], but
not others [10, 15, 16]. Thus, standard measures of injury
severity do not seem to capture the true biological impact
of the trauma. Other associated variables, such as SES, age
at injury and sex, are also not reliable predictors of attention difficulties across studies [10, 11, 14–16].
These attention and executive functioning deficits are
particularly relevant to children and adolescents as they
impact progress in academics and psychosocial development, and may have a negative influence on family
functioning [6, 8, 11]. If clinicians were able to identify
patients at high risk of long-term deficits in attention and
executive functioning, management strategies could be
applied in the early stages of recovery to improve functioning and quality of life for the children with TBI and
their families.
Due to the poor reliability of clinical factors, recent research in childhood TBI has started to focus on the use of
serum biomarkers as predictors of outcome. A few serum
biomarkers, such as neuron specific enolase (NSE), S100
calcium binding protein B (S100B), interleukin-6 (IL-6)
and interleukin-8 (IL-8), have previously been shown to
be associated with global neurological function and cognitive outcomes in children with TBI [17–21]. These studies
did not allow for a comprehensive understanding of postinjury cognitive and behavioural deficits that may occur in
those who appear to have recovered physically and yet still
have serious cognitive sequelae [22].
We conducted a proof of principle study to determine
which combination of injury (Glasgow Coma Scale; GCS)
and child (age at injury, sex, SES, and pre-injury functioning)
variables and six brain-injury and inflammatory serum
protein biomarkers relate to long-term outcome in attention
and executive functioning, as rated by parents, following
childhood TBI. Serum biomarkers S100B, NSE, Il-6 and IL8 were chosen due to their association with outcome
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following paediatric TBI. Soluble neuron cell adhesion
molecule (sNCAM) and soluble vascular cell adhesion
molecule (sVCAM-1) were also measured as potential
biomarkers of microvascular injury and inflammation that
may be associated with outcome following TBI. This study
identifies the characteristics that may be most closely associated with long-term cognitive and behavioural outcome in
attention and executive functioning following paediatric
TBI. We hypothesized a combination of serum biomarkers
[21, 22] will be more strongly associated with long-term
outcome measured at least a year and a half post-injury than
other child and injury related variables, which have been
inconsistently related to cognitive and behavioural outcome
in the past [4, 6–8, 10, 11, 14–16].

Materials and methods
Participants

Children and adolescents with TBI were recruited from
three Ontario children’s hospitals: The Hospital for Sick
Children (SickKids; Toronto), Children’s Hospital at London
Health Sciences Centre (LHSC; London) and McMaster
Children’s Hospital (MCH; Hamilton). Children were recruited from 2009 to 2013 in a prospective observational
study, which included a 12 month follow-up time period
post-injury. For the present study a subgroup of children
were recruited from this convenience sample and asked to
return for a follow-up research study from 2012 to 2015.
Participants returned to complete the follow-up testing at
either SickKids or LHSC. Inclusion criteria for participants
were as follows: diagnosis of mild to severe TBI, aged 2.5–
17 years old at injury time, parents or guardians were
English-speaking and consented to the study. Written informed consent was obtained from participants 18 years old
or from parents/guardians of those under 18 years along
with assent from the minor participants. Participants were
excluded at the time of follow-up if they were over the age
of 19 years, as the questionnaires used are not normalized
for those over 18.9 years. Recruitment details can be found
in Fig. 1. The data were obtained following review by ethics
boards at all participating hospitals and in compliance with
Canadian National Research Council standards.
Methods and measures

Using a procedures manual, trained research coordinators
collected information on demographics and injury variables. TBI severity was determined by selecting the highest
(i.e., the best) of two GCS scores recorded at the scene of
the accident and once admitted to hospital. SES was recorded for each participant at the time of follow-up only.
As an estimate for SES, parents or guardians were asked to
select one of seven categories to indicate total family
income (i.e. choices ranged from less than $20,000 to
greater than $70,000).
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Fig. 1 Number of children enrolled in study

In the acute phase following injury, serum biomarkers
were collected and caregivers were administered a questionnaire to assess pre-injury functioning of the patient.
Daily blood samples, collected during morning blood work
for up to two weeks post-injury, were allowed to clot in a
tube with no anticoagulant, centrifuged at 5000 rpm at 4
degrees centigrade (°C) for 10 min, and then separated into
100 μl aliquots. Samples were initially stored at the collecting hospital at −80 °C and then shipped on dry ice and
stored at −80 °C at SickKids in a biobank. A laboratory
technician, blinded to patient information, completed the
biomarker measurements at the Analytical Facility for
Bioactive Molecules (SickKids). The following multiplex
immunoassays (Millipore-EMD, Billerica, MD, USA) were
run on a Luminex 200 using xPonent 3.1.971.0 software
(Luminex Corporation, Austin, TX, USA): NSE - MILLIPLEX MAP Human Cancer/Metastasis Biomarker Magnetic Bead Panel – Cancer Multiplex Assay; IL-6 and IL-8 MILLIPLEX MAP Human Cytokine/Chemokine Magnetic
Bead Panel – Immunology Multiple Assay; sVCAM-1 and

sNCAM - MILLIPLEX MAP Human Neurodegenerative
Disease Magnetic Bead Panel 3 – Neuroscience Multiplex
Assay. Also, S100B was measured using Human S100B
enzyme linked immunosorbent assay (ELISA) kits. All
measurements were conducted using the manufacturers’
instructions.
The highest of the collected levels was determined for
five of the six sampled biomarkers for each patient. The
highest levels were chosen as opposed to initial levels as
serum concentration levels peak at different times for each
biomarker and the initial level may not be fully representative of the extent of the injury [19]. The lowest level of
sNCAM was selected, as a decrease in this biomarker has
been seen following TBI. Blood was drawn for each
participant once each day as long as blood was sampled
for clinical monitoring. If blood was only drawn once, the
serum biomarker levels taken at that time for the patient
were used as a proxy for the highest or lowest level.
The Pediatric Injury Functional Outcome Scale (PIFOS)
is a brief injury-specific rating scale for children aged 3 to
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15 years administered through a caregiver interview by a
trained health care provider [23]. It assesses six areas of
function: motor skills, daily living skills, communications,
social-emotional, cognition and physical changes. It consists
of 26 items and uses a four-point scale (0 = no change from
preinjury levels; 2 to 4 = increasing need for support and
limitations to daily activities). Thus, higher PIFOS scores
reflect greater difficulties. The PIFOS was validated by
relating it to multiple global and neuropsychological measures, including the Behavior Rating Inventory of Executive
Function (BRIEF) [23]. In order to adapt the PIFOS as a
measure of pre-injury functioning, the PIFOS questions
were rewritten to be posed in the past tense and included
the addition of ‘prior to injury’ at the end of each question.
A score of 0 was taken to mean no concerns in the area
being assessed, while scores of 2 to 4 represented any
supports or limitations to daily activities needed pre-injury.
The PIFOS was completed by a parent or guardian as a
level of ‘baseline’ functioning soon after the child was
admitted to hospital with a TBI.
Patients were asked to return for follow-up assessment
at least one year following injury. Patients recruited from
SickKids and MCH completed follow-up assessment at
SickKids, while those recruited from LHSC completed
follow-up at LHSC. When patients returned for the longterm follow-up, parents were asked to complete the following questionnaires as per the publishers’ instructions.
The BRIEF – Parent Form is a parent questionnaire
designed to assess different aspects of executive functioning
behaviours in the home environment in children and adolescents aged 5–18 years. It is divided into the Behavioral
Regulation Index (BRI) and Metacognition Index (MI). The
BRI is made up of three clinical scales: inhibit, shift and
emotional control; while, the MI is made up of five clinical
scales: initiate, working memory, plan/organize, organization
of materials and monitor [24].
The Conners 3rd Edition Rating Scales (Conners-3) –
Parent Form is a parent questionnaire used to assess
ADHD and its most common associated problems and
disorders in youth aged 6–18 years. The questionnaire
consists of six content scales: inattention, hyperactivity/
impulsivity, learning problems, executive functioning,
peer relations and defiance/aggression [25].
For both the BRIEF and Conners-3, raw scores for each
content scale are converted into standardized T-scores,
normed for both age and sex. T-scores have a mean of 50
and a standard deviation of 10. Higher T-scores are associated with greater parent-reported concerns, with a T-score
of ≥60 considered to be ‘borderline’ and ≥65 considered to
be clinically significant [24, 25].
Statistical analyses

Associations between injury characteristics, serum biomarkers and behavioural measures were analyzed using a
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partial least squares (PLS) analysis. PLS allows for more accurate predictions than multiple regression derived models,
as it can include multiple outcome predictors and has
greater stability in handling multicollinearity between variables [26]. PLS identifies patterns between independent and
dependent variables. Specifically, the covariance between
independent (X) and dependent (Y) variables is decomposed into components, and these components represent
contributions of predictor variables to a pattern of outcome
variables. We performed three separate PLS analyses. The
predictors were consistent for each analysis and included
age at injury, GCS, sex, SES, PIFOS Total score, PIFOS
Cognition score, highest levels of S100B, NSE, IL-6, IL-8,
sVCAM and lowest levels of sNCAM. These predictors
represent individual and injury characteristics and serum
biomarkers. The set of outcome variables were different for
each analysis. The first analysis looked at all six content
scales of the Conners-3, the second looked at the three clinical scales of the BRIEF BRI and the third examined the five
clinical scales of the BRIEF MI. All continuous variables for
the predictors and outcomes were z-scored, and noncontinuous variables (sex and SES) were zero-centred.
The PLS analyses were performed using a combination of
MATLAB (Mathworks Inc., Natick MA) and R statistical
software. First, using the polycor package in R, a heterogeneous correlation matrix was calculated between each X and
Y data matrix. This method computes Pearson correlations
between two continuous variables, polyserial correlations
between numeric and discrete variables, and polychoric correlations between two discrete variables. Next, this correlation matrix was decomposed using singular value
decomposition (SVD) to obtain orthogonal components, or
patterns, which maximize the correlation between predictor
and outcome measures. Statistical significance of contributions to each pattern was then computed using bootstrap resampling. The above calculations were performed 5000
times, using random sampling with replacement. On each
iteration, an alignment of the eigenvectors (found in the
SVD) to the original, non-bootstrapped data was performed.
In cases with more than one dependent variable, a Procrustes
rotation performed this alignment. Bootstrap ratios were
calculated from these distributions, and can be interpreted
as a z-score [27]. Significance threshold was set at
|Z| > 2.58. The number of components found from SVD
equals the number of outcome variables used in the
analysis. Significance of a component was determined
using an eigenvalue >1 (as found from the SVD). To
visualize these patterns, the significant contributors from
each analysis were plotted with 95% prediction intervals,
as calculated from bootstrap resampling.
We performed a sensitivity analysis to compare included
participants from those excluded from the study, independent t-tests, for continuous demographic variables, and
Chi-square analyses, for categorical demographic variables,
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were performed. Independent t-tests were also performed
on biomarker levels to compare those included and
excluded from this study.

Table 1 Demographic variables, injury severity, mechanism of injury,
and associated injuries

Results
Twenty-nine of the 85 children and adolescents who were
recruited into the original study completed an extended
follow-up assessment at more than one year post-injury. Of
these participants, 23 had serum biomarkers measured at
time of injury and returned completed questionnaires at a
long-term follow-up time point, and thus were analyzed in
the present study. The patient demographics, injury severity,
injury mechanisms and associated injuries are shown in
Table 1. Participants included in the follow-up did not differ
significantly in terms of demographics and injury characteristics from those in the larger cohort of 85 patients with TBI,
who did not participate in this study. However, there were
differences between groups for mechanism of injury.
A summary of serum biomarker levels and the time they
were collected can be found in Table 2. Seven of the 23
participants had only one blood draw. The first blood draw
for these seven participants took place at a mean of 16.51 h
following injury. Figure 2 depicts the change in serum levels
of NSE (Fig. 2a) and sNCAM (Fig. 2b) over days following injury. Mean T-scores for the 23 participants included in the
long-term follow-up portion of the study for the eight clinical
scale scores of the BRIEF can be seen in Table 3 and the six
content scales of the Conners-3 can be seen in Table 4.
Tables 3 and 4 also report the percentage of participants with
borderline or clinically significant T-scores on each scale.
Children were seen at follow-up between the ages 6.0 and
18.8 years [Mean age = 14.1 years, Standard Deviation
(SD) = 4.0 years] and at 1.5 to 5.7 years (Mean time = 3.1 years,
SD = 1.1 years) post-injury.

Age at injury in years; mean (SD)

Characteristic

Full Sample
(n = 85)

Participants
(n = 23)

10.54 (4.7)
Range: 0.0–17.9

10.95 (3.7)
Range: 2.8–15.4

64 (75.3)

14 (60.9)

10 (9)

9 (9)

Mild; n (%)

30 (35.3)

10 (43.5)

Moderate; n (%)

21 (24.7)

4 (17.4)

Severe; n (%)

34 (40.0)

9 (39.1)

Intubated; n (%)

52 (60.5)

13 (56.5)

PIFOS Total Score

5.86 (9.8)

4.59 (5.8)

PIFOS Cognition Score

2.29 (4.6)

1.50 (2.5)

Male; n (%)
GCS; median (IQR)

Mechanism of Injury

n (%)

n (%)

Motor vehicle collision

39 (45.9)

11 (47.8)

Bicycle

14 (16.5)

0 (0)*

Fall

16 (18.8)

5 (21.7)

Sport

7 (8.2)

5 (21.7)*

Other

9 (10.6)

2 (8.7)

CT Findings

n (%)

n (%)

Subdural hematoma

46 (54.1)

11 (47.8)

Epidural hematoma

11 (12.9)

3 (13.0)

Subarachnoid hemorrhage

28 (32.9)

9 (39.1)

Midline shift

13 (15.3)

3 (13.0)

Skull fracture

48 (56.5)

10 (43.5)

Other injuries
Spine fracture

The first PLS analysis revealed one significant component
with an eigenvalue of 1.7, which accounted for 75% of the
total variance. Significant predictor (X) and outcome (Y)
latent variables were determined by their bootstrap ratios,
which can be seen in Table 5. The pattern of association
between these variables revealed that higher levels of
NSE and lower levels of sNCAM were associated with
higher T-scores for inattention, hyperactivity/impulsivity
and executive functioning, as shown in Fig. 3a. The other
predictors did not significantly contribute to this pattern of
outcome measures. Learning problems, aggression and peer
relations were not significantly associated with any pattern
of independent measures.
BRIEF BRI

The second PLS analysis revealed one significant component with an eigenvalue of 1.7, which accounted for 95% of
the total variance. For this component, higher levels of NSE

n (%)
2 (8.7)

Spinal cord injury

3 (3.5)

2 (8.7)

Cardiovascular injury

3 (3.5)

2 (7.1)

18 (20.9)

6 (26.1)

2 (2.3)

1 (4.3)

Thoracic injury

Conners-3

n (%)
6 (7.0)

Abdominal injury

2 (2.3)

1 (4.3)

Major fractures

Genital-urinal injury

28 (32.6)

8 (34.8)

Peripheral injury

2 (2.3)

0 (0.0)

SD standard deviation, IQR interquartile range. Independent t-tests, for continuous
demographic variables, and Chi-square analyses, for categorical demographic
variables, were performed on those included and excluded from the study. *p < .05

were associated with higher T-scores on the inhibit scale.
This relationship can be seen in Fig. 3b, and the bootstrap
ratios can be seen in Table 5. No other predictors were
significantly associated with outcome.
BRIEF MI

The final PLS analysis revealed one significant component
with an eigenvalue of 2.1, which accounted for 89% of the
total variance. The pattern of results among these variables
revealed higher levels of NSE, lower levels of sNCAM and
a higher PIFOS Cognition score to be associated with
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Table 2 Mean (SD) highest biomarker levels and the mean (SD) time the highest levels were sampled
Full Sample (n = 76)

Participants (n = 23)

3.3 (2.4)
Range: 1–12

3.0 (1.9)
Range: 1–7

# of blood draws
Highest Level

Time Sampled (Hours)

Highest Level

Time Sampled (Hours)

333.9 (512.2)
Range: 19.1–3083.4

25.5 (34.3)
Range: 0.7–177.7

500.7 (770.6)
Range: 22.7–3083.4

19.9 (36.6)
Range: 0.7–177.7

NSE (ng/ml)

48.1 (94.8)
Range: 4.1–722.2

42.6 (52.1)
Range: 0.7–219.8

54.7 (146.3)
Range: 4.1–722.2

48.7 (60.3)
Range: 1.1–219.8

IL-6 (pg/ml)

143.3 (322.0)
Range: 3.7–2471.9

34.5 (45.3)
Range: 1.3–287.8

115.3 (194.5)
Range: 3.7–745.5

45.8 (63.5)
Range: 1.4–287.8

IL-8 (pg/ml)

79.5 (156.4)
Range: 4.4–1056.9

36.6 (44.6)
Range: 1.3–177.7

53.2 (70.5)
Range: 5.8–328.3

35.3 (48.0)
Range: 1.4–177.7

sVCAM-1 (ng/ml)

1088.8 (386.1)
Range: 601.5–2890.9

45.2 (54.3)
Range: 0.7–219.8

1091.3 (456.8)
Range: 601.5–2773.2

50.1 (59.1)
Range: 1.1–219.8

sNCAM (ng/ml)a

280.3 (105.0)
Range: 10.1–583.8

55.9 (50.5)
Range: 1.3–219.8

284.8 (96.4)
Range: 115.3–447.5

52.2 (51.6)
Range: 1.4–219.8

S100B (pg/ml)

The full names of each biomarker and their abbreviations can be found in the methods section of the manuscript. ng/ml = nanograms per millilitre; pg/ml = picograms
per millilitre. No significant differences were found on independent t-tests performed on biomarker levels for those included in this study and those excluded.
a
Mean highest levels of biomarkers were calculated for all except sNCAM, for which the lowest level was used

higher T-scores on the initiate and working memory scales
(see Fig. 3c). Bootstrap ratios for the MI predictors can also
be seen in Table 5. The other predictors were not significantly associated with MI outcome.

Discussion
We identified associations between time of injury variables
and cognitive and behavioural outcomes as measured by
parent questionnaires. PLS analyses revealed similar
patterns of associations between the predictors and all
three sets of outcome variables. In a sample of 23 children
who had experienced a TBI and were seen at follow-up an
average of 3.1 years post-injury, we found that the combination of highest levels of NSE and the lowest measured
levels of sNCAM were associated with greater difficulties
with inattention, hyperactivity/impulsivity and executive
functioning as measured by the Conners-3. We also found
that a combination of these two biomarkers combined
with a high PIFOS Cognition score was associated with
the initiate and working memory scales of the BRIEF MI.
The highest levels of NSE were also associated with the
inhibit scale of the BRIEF BRI. This profile of predictor
variables measured at the time of injury reflect those who
are at risk for these specific aspects of attention and
executive functioning issues following childhood TBI.
The use of PLS is well suited for this study, as this technique allows the evaluation of large numbers of variables
with high multicollinearity, in a relatively small sample and
provides insight into the multivariate relations among
predictors and outcome variables [26]. In addition to the
associations we found between serum biomarkers and outcome, we found that not all pre-injury risk factors and injury characteristics were predictive of cognitive and
behavioural outcomes. This is an important consideration

as the variables included in this study are routinely used
when studying outcome. Injury severity (as measured by
GCS), age at injury, SES and sex have been related to cognitive outcome in various studies [1, 4, 6–8, 10, 11, 14–16].
Here, none of those variables were significantly associated;
instead we showed a set of specific variables measured at
the time of injury were related to long-term attention and
executive functioning outcome.
Predicting individual outcomes following TBI based upon
pre-injury variables and injury characteristics is an important undertaking. To our knowledge, this is the first study to
report on serum biomarkers and long-term cognitive outcomes. Interestingly, the same two biomarkers were consistently part of the clinical profiles associated with
outcome. Serum NSE was a significant predictor in all three
PLS analyses and serum sNCAM was a significant
predictor in two of the analyses. It has been hypothesized
that a combination of serum biomarkers or a combination
of biomarkers and injury severity would most likely be the
best predictors of outcome [21]. NSE has been shown to
relate to global outcome using the Glasgow Outcome Scale
(a five point scale assessing physical disability) [18–20], but
sNCAM has not been previously studied in relation to
outcome following paediatric TBI. In a related study, we
investigated nine serum biomarkers and their relations to
the inattention content scale of the Conners-3 measured
12 months after TBI. While sNCAM was found to be a
moderate predictor of inattention at 12 months post-injury,
we found the combination of NSE with pre-injury estimates
of inattention was the strongest predictor of inattention at
12 months post-injury [28]. The present study has also
shown a relation between NSE and sNCAM with three of
the Conners-3 content scales at a longer follow-up time,
including inattention.
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Fig. 2 Change in NSE and sNCAM over time following injury. Legend: The distributions of NSE (a) and sNCAM (b) for each time point are
represented by schematic boxplots. The box represents the interquartile range (IQR; edges are 25% and 75%), the line through the middle of each
box represents the median and the diamond represents the mean. The whiskers extending from the box represent the most extreme points in
the group that lie within the fences. The upper fence is defined as the third quartile plus 1.5 times the IQR and the lower fence is defined as the
first quartile minus 1.5 times the IQR. The circles represent outliers, which fall outside of the fences

The two content scales of the Conners-3, inattention
and hyperactivity/impulsivity, that were part of the outcome profile of the first PLS analysis are the primary
symptoms of ADHD [9, 25], which we know is frequently
seen in children following TBI [10–12]. These ADHD
symptoms have been seen in the chronic stages following
injury in previous studies [9, 14], and we have now shown
a relation with these symptoms measured in the chronic
stages following injury and serum biomarkers measured in
the acute period following injury. The executive functioning content scale from the Conners-3 was also part of the
outcome profile found in the first PLS analysis. The BRIEF

allowed for a more in-depth evaluation of executive
functioning outcome in the second and third PLS analyses. To our knowledge, this is the first study to report
the relations between serum biomarkers and parentreported executive functioning following TBI, although
other investigators have found long-term deficits in executive functioning post TBI [4, 7, 8]. These studies reported
significant declines on the two index scores and the composite score of the BRIEF in children with TBI, but Sesma
and colleagues [7] reported significant differences in all of
the clinical scales except organization of materials, between children with TBI at a year following injury when

Wilkinson et al. BMC Pediatrics (2017) 17:173

Page 8 of 11

Table 3 Participant results on the clinical scales of the BRIEF

Table 5 Bootstrap ratios of predictors and outcomes for the
three Partial Least Square analyses

BRIEF Scales

T Scores;
mean (SD)

n (%) with
T-Scores ≥60

n (%) with
T-Scores ≥65

Inhibit

57.09 (15.1)

8 (34.8)

5 (21.7)

Age at Injury

−0.02

−1.32

−1.86

Shift

59.78 (15.0)

12 (53.2)

8 (34.8)

Sex

−2.32

−2.22

−0.94

Emotional Control

55.78 (12.9)

8 (34.8)

5 (21.7)

GCS

0.67

1.54

0.42

Behavioural Regulation
Index (BRI)

58.35 (15.1)

9 (39.1)

6 (26.1)

SES

−1.90

−0.61

−1.23

Initiate

56.87 (14.6)

9 (39.1)

7 (30.4)

PIFOS Total Score

−0.52

−0.25

1.53

Working Memory

60.30 (15.6)

9 (39.1)

8 (34.8)

PIFOS Cognition Score

0.39

0.60

3.09*

Plan/Organize

59.96 (13.6)

9 (39.1)

7 (30.4)

Organization of
Materials

53.61 (11.1)

7 (30.4)

5 (21.7)

Variables

PLS 1

PLS 2

PLS 3

S100B

1.76

1.40

−0.31

NSE

3.20*

3.17*

3.98*

IL-6

0.78

−0.02

0.62

0.43

−0.01

0.97

Monitor

56.91 (12.6)

8 (34.8)

7 (30.4)

IL-8

Metacognition
Index (MI)

59.04 (13.4)

9 (39.1)

8 (34.8)

sVCAM

2.10

1.77

2.20

sNCAM

−2.81*

−2.04

−4.19*

Global Executive
Composite (GEC)

59.35 (14.8)

4.25*

-

-

10 (43.5)

9 (39.1)
Conners-3 Content Scales

The means and standard deviations of the T-Scores of the BRIEF clinical scales.
The number and percentage of the 23 participants with clinically elevated
symptoms on each scale are also presented

compared to both baseline scores and a control group.
Working memory was the only clinical scale of the BRIEF
that was consistently significantly different following TBI
regardless of the severity of TBI or time over the first year
following injury. In this current study, working memory was
one of the three clinical scales of the BRIEF significantly
related to predictors in the two PLS models. A variety of
executive functions are evidently impaired following TBI.
The significant association between scales from both
questionnaires and serum biomarkers NSE and sNCAM
suggests that these serum biomarkers reflect significant
brain injury that has long-term sequelae. NSE is a glycolytic
enzyme found primarily in the cytoplasm of neurons and
released into extracellular space as a result of neuron damage [29]. sNCAM is a binding glycoprotein expressed on
the surface of neurons which helps promote neurite outgrowth and is passively released upon cell destruction [30].
Future studies should further characterize the predictive
Table 4 Participant results on the content scales of the
Conners-3
Conners-3
Content Scales

T Scores;
mean (SD)

n (%) with
T-Scores ≥60

n (%) with
T-Scores ≥65

Inattention

63.09 (15.6)

12 (53.2)

10 (43.5)

Hyperactivity/Impulsivity

61.04 (16.0)

10 (43.5)

9 (39.1)

Learning Problems

58.70 (11.9)

11 (47.8)

9 (39.1)

Executive Functioning

59.73 (13.5)

10 (43.5)

8 (34.8)

Defiance/Aggression

57.74 (15.8)

7 (30.4)

7 (30.4)

Peer Relations

57.70 (15.7)

9 (39.1)

6 (26.1)

The means and standard deviations of the T-Scores of the Conners-3 content
scales. The number and percentage of the 23 participants with clinically
elevated symptoms on each scale are also presented

Inattention
Hyperactivity/Impulsivity

3.23*

-

-

Executive Functioning

3.09*

-

-

Learning Problems

−0.01

-

-

Defiance/Aggression

0.06

-

-

Peer Relations

−0.13

-

-

Inhibit

-

3.30*

-

Shift

-

0.06

-

Emotional Control

-

1.92

-

Initiate

-

-

3.91*

Working Memory

-

-

6.72*

Plan/Organize

-

-

0.94

Organization of Materials

-

-

−1.04

Monitor

-

-

0.52

BRIEF BRI Scales

BRIEF MI Scales

The bootstrap ratios are presented for the three Partial Least Squares (PLS)
analyses conducted. The bootstrap ratios (z-scores) for the predictor variables
are presented in the top half of the table, while the bootstrap ratios for the
outcome variables are presented in the bottom half of the table. *Signifies
significant differences between the latent variable and the null hypothesis

power of these two serum biomarkers in predicting cognitive outcome following paediatric and adult TBI.
For the current study, we did not have pre-injury
Conners-3 or BRIEF questionnaires available on all of our
participants to study the impact of pre-injury functioning
on outcome. We did, however, have the PIFOS as a proxy
of pre-injury functioning. The PIFOS Cognition score included questions on judgement/safety, memory, attention,
speed of processing, academic placement and executive
function, and specifically inquires about impulses, planning and organizing activities and problem solving [23].
Many of these questions tap into the indices of the BRIEF
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Fig. 3 PLS analyses results for Conners-3 content scores and the BRIEF
BRI and BRIEF MI clinical scales. Legend: The significant contributions of
the independent (above dotted line) and dependent (below dotted line)
variables to the first component for (a) the Conners-3 content scales
(b) the BRIEF BRI clinical scales and (c) the BRIEF MI clinical scales for
the 23 TBI patients. The lines represent the 95% prediction intervals,
and the ticks on each line represent the median bootstrapped
contribution of each variable. Significant contributions to the
component were determined using a bootstrap ratio (z-score) of >2.58
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and the PIFOS was originally validated by showing relations with the BRIEF [23]. The questions that make up the
PIFOS Cognition score appear to be measuring comparable functions to the clinical scales of the MI rather than
the BRI. Thus, this could explain why the predictor profile
for the MI outcome included the serum biomarkers as
well as the PIFOS Cognition score. This study was
designed prior to 2009, and thus prior to the publication
of the current National Institute of Health (NIH) TBI
common data elements (CDEs) [31]. In accordance with
these recommendations, we are currently also collecting
the GOS-Extended Pediatric Revision (GOS-E Peds) and
other NIH TBI CDEs in ongoing studies.
Parent questionnaires provide ecologically valid assessments of a range of children’s behaviour [8]. The investigation of the relations between serum biomarkers and
cognition through neuropsychological measures would allow,
however, greater insight into these deficits and would be the
obvious next step in the research of serum biomarkers and
long-term cognitive sequelae of TBI. Cognitive interventions
have not been widely researched in childhood TBI, associations between serum biomarkers and neurocognitive outcome could contribute to planning for early interventions
during the acute time period following TBI. Some early studies have shown improvements on the BRIEF and measures
of attention and executive functioning following cognitive
intervention programs including the Attention Improvement
and Management program [32] and a family-centred,
online-counselor-assisted program intervention [33, 34].
This proof of principle revealed promising results, but
before clinical decision making can be directed the results
need to be replicated in a prospective study with a larger
sample size. We acknowledge that we were limited by the
number of blood sample draws available for each patient,
with some patients only having one blood sample drawn, in
particular those with mild TBI. In the current study, we
required informed consent prior to collecting blood samples,
and this may have led to missing the highest serum levels
for biomarkers that peak early, such as S100B. In subsequent
studies, Research Ethics Boards at hospitals in Canada and
Australia have provided permission to use a deferred
consent model, allowing the collection of daily blood
samples up to 48 h prior to obtaining informed consent.
Additionally, further understanding of these serum
biomarkers in both injured and non-injured children is
needed. Collecting medically unnecessary blood samples
from typically developing controls is a difficult task in the
paediatric population, both from a participant and a
Research Ethics Board standpoint. One previous study found
no significant difference in NSE and S100B levels between
two control groups recruited from those undergoing routine
blood work or with isolated fractures, but did see significant
differences in biomarker levels between these controls and
those with head injury [35]. Some of the biomarkers that we
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investigated in this study are released as a result of injuries to
other parts of the body, as outlined in Table 1. Thus, another
excellent control group could be those undergoing care for
serious injuries without head injury. Future studies should
carefully consider the addition of injured and non-injured
control groups, as well as the impact of activity to the serum
biomarker levels of the patients prior to incurring the injury.

Ethics approval and consent to participate
Participants were recruited for follow-up from two different research studies at
three Ontario Children’s Hospitals. Ethical approval was granted from Hospital
for Sick Children (Research Ethics Board Approval numbers 1,000,022,462 and
1,000,012,562), Children’s Hospital at London Health Sciences Centre (UWO HSREB
Full Board Submission (June 2008)) and McMaster Children’s Hospital (Hamilton
Research Ethics Board: project number 09–210). Written informed consent
(participants over 18 years and parents/guardians of participants under 18 years)
and assent (participants under 18 years) was collected for all participants.

Conclusions
Following TBI, children are at risk of persistent attention
and executive functioning problems. In this proof of
principle study, we showed a relation between the serum
biomarkers, NSE and sNCAM, with long-term outcome on
the Conners-3 and BRIEF. For the MI from the BRIEF, this
relationship included a combination of these biomarkers
with the PIFOS Cognition score, while the BRI from the
BRIEF was only associated with NSE. When validated in
future research studies, these associations could improve
clinical decisions, prediction of long-term outcome and
planning during the acute time period following TBI.
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